UNSPSC 51384904: Quillifoline

This classification denotes an analgesic agent with the molecular formula C21H24ClNO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8JD13PH39Q, chemically known as 2-(p-chlorophenyl)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo(a)quinolizine but more generally known as quillifoline, which bears U.S. National Institutes of Health Compound Identifier 160353. The European Medicines Agency schedules Quillifoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10195MIG.

The term QUILLIFOLINE is an International Non-Proprietary Name. QUILLIFOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C2CC3N(CC2)CCC2C3CC(OC)C(OC)C2)CC1.

UNSPSC 51384904 Quillifoline is a Commodity code. Recent state and local procurement activity under this code shows little relevance to quillifoline itself; instead, issuing bodies are soliciting naloxone, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products through a mix of direct purchase, cooperative purchasing, and information-gathering mechanisms. The work spans health and human services agencies acquiring pharmaceutical products and related medical supplies to support community health initiatives, state pharmacy benefit programs, and multistate cooperative purchasing networks. Issuing bodies include county health departments, state health and human services commissions, and state procurement offices administering cooperative purchasing alliances.

Recent opportunities reflect activity across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery requirements and fixed-fee pricing. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct-contracting models outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities, with awards effective July 1, 2026, and price competitiveness weighted at 75 percent of the evaluation.